Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index; 3 of the 18 sources its claims cite were checked for support.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Open access

Abstract

Background: The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter gut microbiota diversity and composition leading to dysbiosis, which may affect effectiveness of ICI. Patients and methods: We examined patients with advanced renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) treated with anti-programmed cell death ligand-1 mAb monotherapy or combination at two academic institutions. Those receiving ATB within 30 days of beginning ICI were compared with those who did not. Objective response, progression-free survival (PFS) determined by RECIST1.1 and overall survival (OS) were assessed. Results: Sixteen of 121 (13%) RCC patients and 48 of 239 (20%) NSCLC patients received ATB. The most common ATB were β-lactam or quinolones for pneumonia or urinary tract infections. In RCC patients, ATB compared with no ATB was associated with increased risk of primary progressive disease (PD) (75% versus 22%, P < 0.01), shorter PFS [median 1.9 versus 7.4 months, hazard ratio (HR) 3.1, 95% confidence interval (CI) 1.4-6.9, P < 0.01], and shorter OS (median 17.3 versus 30.6 months, HR 3.5, 95% CI 1.1-10.8, P = 0.03). In NSCLC patients, ATB was associated with similar rates of primary PD (52% versus 43%, P = 0.26) but decreased PFS (median 1.9 versus 3.8 months, HR 1.5, 95% CI 1.0-2.2, P = 0.03) and OS (median 7.9 versus 24.6 months, HR 4.4, 95% CI 2.6-7.7, P < 0.01). In multivariate analyses, the impact of ATB remained significant for PFS in RCC and for OS in NSCLC. Conclusion: ATB were associated with reduced clinical benefit from ICI in RCC and NSCLC. Modulatation of ATB-related dysbiosis and gut microbiota composition may be a strategy to improve clinical outcomes with ICI.

Overview

CoChat Summary

TL;DR

In two independent cohorts of advanced RCC and NSCLC treated with immune checkpoint inhibitors, antibiotic use within 30 days before starting therapy was associated with worse clinical outcomes. The association remained significant for PFS in RCC and for OS in NSCLC in multivariate analyses.

Key findings

  • Among 121 RCC patients, 16 (13%) received antibiotics within 30 days of starting ICI. Antibiotic use was associated with more primary progressive disease (75% versus 22%, P < 0.01), shorter median PFS (1.9 versus 7.4 months; HR 3.1, 95% CI 1.4–6.9, P < 0.01), and shorter median OS (17.3 versus 30.6 months; HR 3.5, 95% CI 1.1–10.8, P = 0.03).
  • Among 239 NSCLC patients, 48 (20%) received antibiotics within 30 days. Antibiotic use was not associated with primary PD (52% versus 43%, P = 0.26) but was associated with shorter median PFS (1.9 versus 3.8 months; HR 1.5, 95% CI 1.0–2.2, P = 0.03) and shorter median OS (7.9 versus 24.6 months; HR 4.4, 95% CI 2.6–7.7, P < 0.01).
  • In multivariate analysis, antibiotics remained associated with worse PFS in RCC (HR 2.0, P < 0.01) but not OS (HR 2.1, P = 0.11); in NSCLC, antibiotics were not significantly associated with PFS (HR 1.3, 95% CI 0.9–1.8, P = 0.17) but remained associated with worse OS (HR 2.5, 95% CI 1.6–3.7, P < 0.01).
  • With a 60-day antibiotic window, RCC showed shorter PFS (median 3.1 versus 7.4 months; HR 2.3, 95% CI 1.2–4.4, P < 0.01) and a trend toward worse OS (median 23.4 versus 30 months; HR 1.9, 95% CI 0.8–4.7, P = 0.15); NSCLC showed no difference in objective response or PFS but shorter OS (median 9.8 versus 21.9 months; HR 2.0, 95% CI 1.3–3.2, P < 0.01).

Methods

  • Retrospective review of patients with advanced RCC (n = 121) at Gustave Roussy and NSCLC (n = 239) at Memorial Sloan Kettering Cancer Center treated with anti-PD-(L)1 monoclonal antibody monotherapy or combination therapy.
  • Antibiotic use was assessed within 30 days or up to 60 days before the first ICI injection; antibiotic class, indication, route, and duration were collected.
  • Tumor response was determined by RECIST 1.1; PFS and OS were estimated by Kaplan–Meier and compared with log-rank tests, with multivariable Cox regression adjusting for clinicopathologic features.

Limitations

  • The authors state the study is retrospective, with data entry from two institutions; although responses were reviewed with RECIST 1.1, scan timing was not prespecified.
  • The authors note differences in patient characteristics between antibiotic and no-antibiotic groups, including higher recent hospitalization in NSCLC and differences in prior lines in RCC, and that analyses did not account for diet, country of origin, or other medications.
  • The authors state they did not characterize the mechanism by which antibiotics affect outcomes, and PD-L1 status was lacking in most patients; the text also makes evident that antibiotic subgroups were small and immune-related adverse events were too few to evaluate.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy103

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY-NC-ND · From the PDF
Image 2
CC-BY-NC-ND · From the PDF
Figure 1 Best overall response (A), progression-free survival (PFS) (B), and overall survival (OS) (C) in patients with RCC treated with ICI, stratified by use of ATB within 30 days of initiating ICI. Best overall response (D), PFS (E), and OS (F) in patients with NSCLC treated with ICI, stratified by use of ATB within 30 days of initiating ICI. P -values calculated with chi-squared and log-rank tests.
Figure 1 Best overall response (A), progression-free survival (PFS) (B), and overall survival (OS) (C) in patients with RCC treated with ICI, stratified by use of ATB within 30 days of initiating ICI. Best overall response (D), PFS (E), and OS (F) in patients with NSCLC treated with ICI, stratified by use of ATB within 30 days of initiating ICI. P -values calculated with chi-squared and log-rank tests.CC-BY-NC-ND · From the PDF
Figure 2 Subgroup analyses of independent prognostic factors for PFS (A and B) and OS (C and D) stratification in RCC and NSCLC, respectively. P -value for interaction calculated with Cox proportional hazards model.
Figure 2 Subgroup analyses of independent prognostic factors for PFS (A and B) and OS (C and D) stratification in RCC and NSCLC, respectively. P -value for interaction calculated with Cox proportional hazards model.CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
Image 6
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

2 Valid · 1 Not valid · 7 Not checked · 33 Own results and interpretations

20 more claims

Create a free account to see all 43 claims and to verify the 15 references still open.

See all claims — free account
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 9 · the rest aren’t loaded

4 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 39 references

Cited by

See all 909

Metadata

Authors
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., Rouche, J. A., Zitvogel, L., Zalcman, G., Albiges, L., Escudier, B., & Routy, B.
Affiliations
  • Université Paris-Sud (FR)
  • Memorial Sloan Kettering Cancer Center (US)
  • McGill University (CA)
  • Institut Gustave Roussy (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Routy, B.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-06
Volume
29
Issue
6
Pages
1437-1444
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2795186863
Cited by
908
References
39
Citations by year
2026: 94 · 2025: 94 · 2024: 86 · 2023: 119 · 2022: 133 · 2021: 143 · 2020: 126 · 2019: 93 · 2018: 19
FWCI
35.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Gustave Roussy Fondation Philanthropia
  • RK Smiley Canadian Hematology Society
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
antibiotics, immune checkpoint inhibitors, PD-1/PD-L1 blockade, renal cell carcinoma, non-small cell lung cancer, gut microbiota, dysbiosis, progression-free survival, overall survival, antitumor immunity, beta-lactam antibiotics, quinolones, immunotherapy response
MeSH terms
Antineoplastic Agents, Immunological, Nivolumab, Aged, Anti-Bacterial Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Immunotherapy, Kidney Neoplasms, Lung Neoplasms, Male, Prognosis, Survival Rate, Cell Cycle Checkpoints, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. https://app.cochat.ai/papers/10.1093/annonc/mdy103
The paper
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., Rouche, J. A., Zitvogel, L., Zalcman, G., Albiges, L., Escudier, B., & Routy, B. (2018). Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdy103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.